- Home
- FDMT
as 02-21-2025 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 268.6M | IPO Year: | 2020 |
| Target Price: | $36.33 | AVG Volume (30 days): | 957.1K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.41 - $36.25 | Next Earning Date: | 03-03-2025 |
| Revenue: | $17,000 | Revenue Growth: | -99.92% |
| Revenue Growth (this year): | -92.63% | Revenue Growth (next year): | 159.36% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
4DMT to Participate in Upcoming Investor Conferences
MT Newswires
11 days ago
Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating
GlobeNewswire
14 days ago
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
GlobeNewswire
24 days ago
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Simply Wall St.
a month ago
Top US Penny Stocks To Watch In January 2025
MT Newswires
a month ago
BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40
MT Newswires
a month ago
4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates
GlobeNewswire
a month ago
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.